These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 18476294)

  • 21. Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.
    Gillette M; Taylor A; Butulija D; Kadiyala H; Jneid H
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):579-584. PubMed ID: 32318933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
    Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects for productivity.
    Booth B; Zemmel R
    Nat Rev Drug Discov; 2004 May; 3(5):451-6. PubMed ID: 15136792
    [No Abstract]   [Full Text] [Related]  

  • 25. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Faster evaluation of vital drugs.
    Kessler DA; Feiden KL
    Sci Am; 1995 Mar; 272(3):48-54. PubMed ID: 7871409
    [No Abstract]   [Full Text] [Related]  

  • 27. [The long path (s) of placing medicines on the market].
    Duguet C
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
    [No Abstract]   [Full Text] [Related]  

  • 28. Assessment of value and applications of in vitro testing of topical dermatological drug products.
    Flynn GL; Shah VP; Tenjarla SN; Corbo M; DeMagistris D; Feldman TG; Franz TJ; Miran DR; Pearce DM; Sequeira JA; Swarbrick J; Wang JC; Yacobi A; Zatz JL
    Pharm Res; 1999 Sep; 16(9):1325-30. PubMed ID: 10496646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. US FDA feels the heat from Congressional hearings.
    Loewenberg S
    Lancet; 2008 May; 371(9624):1565-6. PubMed ID: 18476294
    [No Abstract]   [Full Text] [Related]  

  • 30. Does neurology need a faster FDA?
    Burton A
    Lancet Neurol; 2014 Aug; 13(8):760-1. PubMed ID: 25030510
    [No Abstract]   [Full Text] [Related]  

  • 31. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

  • 33. Triazolam treatment controversy.
    Ghaeli P; Dufresne RL; Stoukides CA
    Ann Pharmacother; 1994 Sep; 28(9):1038-40. PubMed ID: 7803879
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.